{"name":"Hongjia Zhang","slug":"hongjia-zhang","ticker":"","exchange":"","domain":"","description":"Hongjia Zhang is a pharmaceutical company with a focus on developing and marketing fibrinogen concentrate, a critical component in hemostasis and blood clotting. The company operates with a specialized portfolio and is dedicated to advancing treatments in the field of hemostasis.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"fibrinogen concentrate","genericName":"fibrinogen concentrate","slug":"fibrinogen-concentrate","indication":"Other","status":"marketed"}]}],"pipeline":[{"name":"fibrinogen concentrate","genericName":"fibrinogen concentrate","slug":"fibrinogen-concentrate","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":1,"phaseCounts":{"marketed":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}